Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum

Journal of Neural Transmission

Volumn 108, Issue 4, 2001, Pages 431-444

  Naudon, L ^a   Leroux Nicollet, I ^a   Boulay, D ^b   Costentin, J ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b SANOFI   (France)

Author keywords

Dopamine transporter; Kainic acid lesion; Serotonin transporter; Striatum; Vesicular monoamine transporter 2

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINESTERASE; CARRIER PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; KAINIC ACID; MAZINDOL; MONOAMINE; SEROTONIN; SEROTONIN TRANSPORTER; TRITIUM; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN INJURY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; NERVE DEGENERATION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITALOPRAM; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; EXCITATORY AMINO ACID AGONISTS; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; KAINIC ACID; MALE; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEUROPEPTIDES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TETRABENAZINE; TRITIUM; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0034895779     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170064     Document Type: Article

References (38)

1. Compensatory bilateral changes in dopamine turnover after striatal kainate lesion
2. Local injection of excitatory amino acid agonist alters the glutamatergic and dopaminergic transmission in the rat striatum
3. Functional damage of dopamine nerve terminals following intrastriatal kainic acid injection
4. 3H]mazindol binding to the dopamine transporter in the nucleus accumbens are delayed after chronic treatments by GBR12783 or cocaine
5. Alterations in striatal neurotrophic activity induced by dopaminergic drugs
6. Excitotoxins
7. In situ injection of kainic acid: A new method for selectively lesioning neuronal cell bodies while sparing axons of passage
8. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters
9. 3H-imipramine
10. Activité des neurones dopaminergiques de la substance noire après lésion du striatum par l'acide kaïnique
11. Long-term local and distal increases in tryptophan hydroxylase activity following intracerebral kainic acid injections in the rat
12. 3H-dopamine release in the rat striatum
13. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine
14. The neostriatal mosaic: Compartmentalization of corticostriatal input and striatonigral output systems
15. Differential effects of kainic acid on dopamine and serotonin metabolism in ventral and dorsal striatum regions
16. Radioligands of the vesicular monoamine transporters and their use as markers of the monoamine storage vesicles
17. 3H mazindol autoradiography
18. 3H-dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum
19. Kainate-induced degeneration of neostriatal neurons: Dependency upon corticostriatal tract
20. Kainic acid neurotoxicity and Huntington's disease
21. In vivo electrochemical measurement of the long-lasting release of dopamine and serotonin induced by intrastriatal kainic acid
22. Kainic acid lesion of the striatum increases dopamine release but reduces 3-methoxytyramine levels
23. Consequences of an intrastriatal injection of kainic acid on the dopaminergic neuronal and vesicular uptake systems
24. Short-term treatments with haloperidol or bromocriptine do no alter the density of the monoamine vesicular transporter in the substantia nigra
25. Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex
26. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites
27. Kainic acid-changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat
28. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments
29. 3H Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity
30. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain
31. Anterograde transport of horseradish peroxidase in the nigrostriatal pathway after neostriatal kainic acid lesions
32. The release of dopamine from nerve terminals and dendrites of nigrostriatal neurons induced by excitatory amino acid in the conscious rat
33. Long-term sequelae of striatal kainate lesion
34. 3H] kainate binding in rat caudate-putamen and nucleus accumbens after 6-hydroxydopamine lesions of the medial forebrain bundle: An autoradiographic study